FDA approves novel corticosteroid treatment option for DMD patients Therapeutics Santhera Pharmaceuticals and partner Catalyst Pharmaceuticals got the FDA’s greenlight for their Duchenne muscular dystrophy drug Agamree, which is expected to launch in the first quarter of 2024. Read more October 27, 2023/by BioSpace https://www.pharmalive.com/wp-content/uploads/2022/05/BioSpacewheelchair5-31-2022.jpg 350 625 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2023-10-27 08:59:562023-10-27 09:31:45FDA approves novel corticosteroid treatment option for DMD patients
